Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Fridolin Sulser.

Sanders-Bush E.

Neuropsychopharmacology. 2016 Dec;41(13):3125-3126. doi: 10.1038/npp.2016.59. No abstract available.

2.

Quantitative trait loci mapping and gene network analysis implicate protocadherin-15 as a determinant of brain serotonin transporter expression.

Ye R, Carneiro AM, Han Q, Airey D, Sanders-Bush E, Zhang B, Lu L, Williams R, Blakely RD.

Genes Brain Behav. 2014 Mar;13(3):261-75. doi: 10.1111/gbb.12119. Epub 2014 Feb 6.

3.

Evaluation of heritable determinants of blood and brain serotonin homeostasis using recombinant inbred mice.

Ye R, Carneiro AM, Airey D, Sanders-Bush E, Williams RW, Lu L, Wang J, Zhang B, Blakely RD.

Genes Brain Behav. 2014 Mar;13(3):247-60. doi: 10.1111/gbb.12092. Epub 2013 Oct 31.

4.

Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior.

Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, Cohen J, Mannangatti P, Jessen T, Thompson BJ, Ye R, Kerr TM, Carneiro AM, Crawley JN, Sanders-Bush E, McMahon DG, Ramamoorthy S, Daws LC, Sutcliffe JS, Blakely RD.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5469-74. doi: 10.1073/pnas.1112345109. Epub 2012 Mar 19.

5.

Impact of RNA editing on functions of the serotonin 2C receptor in vivo.

Olaghere da Silva UB, Morabito MV, Canal CE, Airey DC, Emeson RB, Sanders-Bush E.

Front Neurosci. 2010 Mar 16;4:26. doi: 10.3389/neuro.23.001.2010. eCollection 2010.

6.

National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline.

Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M.

Ann Intern Med. 2010 Aug 3;153(3):176-81. doi: 10.7326/0003-4819-153-3-201008030-00260. Epub 2010 Jun 14.

PMID:
20547888
7.

NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.

Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, Dunbar-Jacob JM, Granieri EC, Hunt G, McGarry K, Patel D, Potosky AL, Sanders-Bush E, Silberberg D, Trevisan M.

NIH Consens State Sci Statements. 2010 Apr 28;27(4):1-30. Review.

8.

The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen.

Canal CE, Olaghere da Silva UB, Gresch PJ, Watt EE, Sanders-Bush E, Airey DC.

Psychopharmacology (Berl). 2010 Apr;209(2):163-74. doi: 10.1007/s00213-010-1784-0. Epub 2010 Feb 19.

9.

An innovative real-time PCR method to measure changes in RNA editing of the serotonin 2C receptor (5-HT(2C)R) in brain.

Lanfranco MF, Seitz PK, Morabito MV, Emeson RB, Sanders-Bush E, Cunningham KA.

J Neurosci Methods. 2009 May 15;179(2):247-57. doi: 10.1016/j.jneumeth.2009.01.027. Epub 2009 Feb 7.

10.

RNA editing of the serotonin 2C receptor and expression of Galpha(q) protein: genetic mouse models do not support a role for regulation or compensation.

Canal CE, Mahautmr KC, Cao C, Sanders-Bush E, Airey DC.

J Neurochem. 2009 Mar;108(5):1136-42. doi: 10.1111/j.1471-4159.2008.05852.x. Epub 2009 Jan 20.

11.

Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A.

Shelton RC, Sanders-Bush E, Manier DH, Lewis DA.

Neuroscience. 2009 Feb 18;158(4):1406-15. doi: 10.1016/j.neuroscience.2008.11.036. Epub 2008 Dec 3.

PMID:
19111907
12.

Centennial perspective: serotonin receptors.

Sanders-Bush E, Airey DC.

Mol Interv. 2008 Oct;8(5):200-3. doi: 10.1124/mi.8.5.1. No abstract available.

PMID:
19015382
13.

Multivariate permutation analysis associates multiple polymorphisms with subphenotypes of major depression.

Hahn MK, Blackford JU, Haman K, Mazei-Robison M, English BA, Prasad HC, Steele A, Hazelwood L, Fentress HM, Myers R, Blakely RD, Sanders-Bush E, Shelton R.

Genes Brain Behav. 2008 Jun;7(4):487-95. Epub 2007 Dec 6.

14.

Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.

Benneyworth MA, Smith RL, Sanders-Bush E.

Neuropsychopharmacology. 2008 Aug;33(9):2206-16. Epub 2007 Oct 24.

15.

A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.

Benneyworth MA, Xiang Z, Smith RL, Garcia EE, Conn PJ, Sanders-Bush E.

Mol Pharmacol. 2007 Aug;72(2):477-84. Epub 2007 May 25.

16.

Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane.

Garcia EE, Smith RL, Sanders-Bush E.

Neuropharmacology. 2007 Jun;52(8):1671-7. Epub 2007 Apr 4.

17.

Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid.

Muldowney JA 3rd, Painter CA, Sanders-Bush E, Brown NJ, Vaughan DE.

Thromb Haemost. 2007 Feb;97(2):263-71.

PMID:
17264956
18.

5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation.

Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, Gore JC, Sanders-Bush E.

J Pharmacol Exp Ther. 2007 Mar;320(3):1023-9. Epub 2006 Nov 30.

19.

5-Hydroxytryptamine (serotonin)2A receptors in rat anterior cingulate cortex mediate the discriminative stimulus properties of d-lysergic acid diethylamide.

Gresch PJ, Barrett RJ, Sanders-Bush E, Smith RL.

J Pharmacol Exp Ther. 2007 Feb;320(2):662-9. Epub 2006 Oct 31.

20.

Universal polyethylene glycol linkers for attaching receptor ligands to quantum dots.

Tomlinson ID, Gies AP, Gresch PJ, Dillard J, Orndorff RL, Sanders-Bush E, Hercules DM, Rosenthal SJ.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6262-6. Epub 2006 Sep 26.

PMID:
17000112
21.

Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression.

Myers RL, Airey DC, Manier DH, Shelton RC, Sanders-Bush E.

Biol Psychiatry. 2007 Jan 15;61(2):167-73. Epub 2006 May 12.

PMID:
16697352
22.

5-HT(2C) receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice.

Hackler EA, Airey DC, Shannon CC, Sodhi MS, Sanders-Bush E.

Neurosci Res. 2006 May;55(1):96-104. Epub 2006 Apr 3.

PMID:
16580757
23.

Surface modification to reduce nonspecific binding of quantum dots in live cell assays.

Bentzen EL, Tomlinson ID, Mason J, Gresch P, Warnement MR, Wright D, Sanders-Bush E, Blakely R, Rosenthal SJ.

Bioconjug Chem. 2005 Nov-Dec;16(6):1488-94.

PMID:
16287246
24.

A rapid new assay to detect RNA editing reveals antipsychotic-induced changes in serotonin-2C transcripts.

Sodhi MS, Airey DC, Lambert W, Burnet PW, Harrison PJ, Sanders-Bush E.

Mol Pharmacol. 2005 Sep;68(3):711-9. Epub 2005 May 25.

25.

Pharmacological properties of the Cys23Ser single nucleotide polymorphism in human 5-HT2C receptor isoforms.

Fentress HM, Grinde E, Mazurkiewicz JE, Backstrom JR, Herrick-Davis K, Sanders-Bush E.

Pharmacogenomics J. 2005;5(4):244-54.

PMID:
15912142
26.

Behavioral tolerance to lysergic acid diethylamide is associated with reduced serotonin-2A receptor signaling in rat cortex.

Gresch PJ, Smith RL, Barrett RJ, Sanders-Bush E.

Neuropsychopharmacology. 2005 Sep;30(9):1693-702.

27.

Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice.

Benneyworth MA, Smith RL, Barrett RJ, Sanders-Bush E.

Psychopharmacology (Berl). 2005 Jun;179(4):854-62. Epub 2005 Jan 12.

PMID:
15645221
28.

Signal transduction abnormalities in melancholic depression.

Akin D, Manier DH, Sanders-Bush E, Shelton RC.

Int J Neuropsychopharmacol. 2005 Mar;8(1):5-16. Epub 2004 Oct 22.

PMID:
15500705
29.

His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation.

Hazelwood LA, Sanders-Bush E.

Mol Pharmacol. 2004 Nov;66(5):1293-300.

31.

Decreased serotonin 5-HT2A receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.

Akin D, Manier DH, Sanders-Bush E, Shelton RC.

Neuropsychopharmacology. 2004 Nov;29(11):2081-7.

32.

Serotonin and brain development.

Sodhi MS, Sanders-Bush E.

Int Rev Neurobiol. 2004;59:111-74. Review.

PMID:
15006487
33.

Serotonin 5-ht2 receptors: molecular and genomic diversity.

Sanders-Bush E, Fentress H, Hazelwood L.

Mol Interv. 2003 Sep;3(6):319-30. Review. No abstract available.

PMID:
14993464
34.

RNA editing of the human serotonin 5-HT2C receptor disrupts transactivation of the small G-protein RhoA.

McGrew L, Price RD, Hackler E, Chang MS, Sanders-Bush E.

Mol Pharmacol. 2004 Jan;65(1):252-6.

35.

Agonist-induced phosphorylation of the serotonin 5-HT2C receptor regulates its interaction with multiple PDZ protein 1.

Parker LL, Backstrom JR, Sanders-Bush E, Shieh BH.

J Biol Chem. 2003 Jun 13;278(24):21576-83. Epub 2003 Apr 7.

36.

Dynamic changes in prefrontal cortex gene expression following lysergic acid diethylamide administration.

Nichols CD, Garcia EE, Sanders-Bush E.

Brain Res Mol Brain Res. 2003 Mar 17;111(1-2):182-8.

PMID:
12654518
37.

Ultrastructural localization of serotonin2A receptors in the middle layers of the rat prelimbic prefrontal cortex.

Miner LA, Backstrom JR, Sanders-Bush E, Sesack SR.

Neuroscience. 2003;116(1):107-17.

PMID:
12535944
38.

Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice.

Smith RL, Barrett RJ, Sanders-Bush E.

Psychopharmacology (Berl). 2003 Feb;166(1):61-8. Epub 2002 Dec 10.

PMID:
12474110
40.

Hallucinogens and Drosophila: linking serotonin receptor activation to behavior.

Nichols CD, Ronesi J, Pratt W, Sanders-Bush E.

Neuroscience. 2002;115(3):979-84.

PMID:
12435434
41.

Lysergic acid diethylamide-induced Fos expression in rat brain: role of serotonin-2A receptors.

Gresch PJ, Strickland LV, Sanders-Bush E.

Neuroscience. 2002;114(3):707-13.

PMID:
12220572
42.

A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain.

Nichols CD, Sanders-Bush E.

Neuropsychopharmacology. 2002 May;26(5):634-42.

43.

Stimulus generalization by fenfluramine in a quipazine-ketanserin drug discrimination is not dependent on indirect serotonin release.

Smith RL, Gresch PJ, Barrett RJ, Sanders-Bush E.

Pharmacol Biochem Behav. 2002 May;72(1-2):77-85.

PMID:
11900772
44.

Dissecting intracellular signaling pathways with membrane-permeable peptides.

Chang MS, Tam JP, Sanders-Bush E.

Sci STKE. 2000 Aug 29;2000(47):pl1.

PMID:
11752605
46.

RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein.

Price RD, Weiner DM, Chang MS, Sanders-Bush E.

J Biol Chem. 2001 Nov 30;276(48):44663-8. Epub 2001 Sep 25.

47.

RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity.

Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP.

Br J Pharmacol. 2001 Sep;134(2):386-92.

48.

RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy.

Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E.

Neuropsychopharmacology. 2001 May;24(5):478-91.

49.

Distribution of serotonin 5-HT(2A) receptors in afferents of the rat striatum.

Bubser M, Backstrom JR, Sanders-Bush E, Roth BL, Deutch AY.

Synapse. 2001 Mar 15;39(4):297-304.

PMID:
11169779
50.

Supplemental Content

Loading ...
Support Center